This past April marked the 10-year anniversary of the release of the first human genome reference sequence, an epic milestone in the annals of medical science. The use of “first-generation sequencing” required over a decade and almost $3 billion. Today’s NGS technologies can do the same in 3 days for a cost of only $3,000. This represents a remarkable leap in efficiency, making NGS viable even for selected clinical applications. But the real growth in clinical sequencing is yet to come.
Collaboration will demonstrate the powerful advantages of transcriptomic data analysis for prediction of the response to novel cancer therapies
3 days ago
Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq
16 days ago
BeiGene and Singlomics sign license agreement for neutralizing COVID-19 antibodies identifed with scRNA-Seq
19 days ago